147 related articles for article (PubMed ID: 12855640)
1. Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer.
Emberley ED; Niu Y; Njue C; Kliewer EV; Murphy LC; Watson PH
Clin Cancer Res; 2003 Jul; 9(7):2627-31. PubMed ID: 12855640
[TBL] [Abstract][Full Text] [Related]
2. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
3. A putative role for psoriasin in breast tumor progression.
Krop I; März A; Carlsson H; Li X; Bloushtain-Qimron N; Hu M; Gelman R; Sabel MS; Schnitt S; Ramaswamy S; Kleer CG; Enerbäck C; Polyak K
Cancer Res; 2005 Dec; 65(24):11326-34. PubMed ID: 16357139
[TBL] [Abstract][Full Text] [Related]
4. Psoriasin interacts with Jab1 and influences breast cancer progression.
Emberley ED; Niu Y; Leygue E; Tomes L; Gietz RD; Murphy LC; Watson PH
Cancer Res; 2003 Apr; 63(8):1954-61. PubMed ID: 12702588
[TBL] [Abstract][Full Text] [Related]
5. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer.
Skliris GP; Lewis A; Emberley E; Peng B; Weebadda WK; Kemp A; Davie JR; Shiu RP; Watson PH; Murphy LC
Breast Cancer Res Treat; 2007 Jul; 104(1):75-85. PubMed ID: 17009105
[TBL] [Abstract][Full Text] [Related]
7. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
8. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma.
Leygue E; Snell L; Hiller T; Dotzlaw H; Hole K; Murphy LC; Watson PH
Cancer Res; 1996 Oct; 56(20):4606-9. PubMed ID: 8840971
[TBL] [Abstract][Full Text] [Related]
10. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
Davidson B; Konstantinovsky S; Nielsen S; Dong HP; Berner A; Vyberg M; Reich R
Clin Cancer Res; 2004 Nov; 10(21):7335-46. PubMed ID: 15534110
[TBL] [Abstract][Full Text] [Related]
12. Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma.
Turunen N; Karihtala P; Mantyniemi A; Sormunen R; Holmgren A; Kinnula VL; Soini Y
APMIS; 2004 Feb; 112(2):123-32. PubMed ID: 15056229
[TBL] [Abstract][Full Text] [Related]
13. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.
Mehra R; Varambally S; Ding L; Shen R; Sabel MS; Ghosh D; Chinnaiyan AM; Kleer CG
Cancer Res; 2005 Dec; 65(24):11259-64. PubMed ID: 16357129
[TBL] [Abstract][Full Text] [Related]
14. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267
[TBL] [Abstract][Full Text] [Related]
15. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
16. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
17. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.
Pellikainen J; Kataja V; Ropponen K; Kellokoski J; Pietiläinen T; Böhm J; Eskelinen M; Kosma VM
Clin Cancer Res; 2002 Nov; 8(11):3487-95. PubMed ID: 12429639
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
Colleoni M; Viale G; Zahrieh D; Pruneri G; Gentilini O; Veronesi P; Gelber RD; Curigliano G; Torrisi R; Luini A; Intra M; Galimberti V; Renne G; Nolè F; Peruzzotti G; Goldhirsch A
Clin Cancer Res; 2004 Oct; 10(19):6622-8. PubMed ID: 15475452
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of selected immunohistochemical parameters in patients with invasive breast carcinoma concomitant with ductal carcinoma in situ.
Patla A; Rudnicka-Sosin L; Pawlega J; Stachura J
Pol J Pathol; 2002; 53(1):25-7. PubMed ID: 12014222
[TBL] [Abstract][Full Text] [Related]
20. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
